We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
- Authors
Tilburt, Jon C.; Zahrieh, David; Pacyna, Joel E.; Petereit, Daniel G.; Kaur, Judith S.; Rapkin, Bruce D.; Grubb, Robert L.; Chang, George J.; Morris, Michael J.; Kovac, Evan Z.; Babaian, Kara N.; Sloan, Jeff A.; Basch, Ethan M.; Peil, Elizabeth S.; Dueck, Amylou C.; Novotny, Paul J.; Paskett, Electra D.; Buckner, Jan C.; Joyce, Daniel D.; Montori, Victor M.
- Abstract
Background: Decision aids (DAs) can improve knowledge for prostate cancer treatment. However, the relative effects of DAs delivered within the clinical encounter and in more diverse patient populations are unknown. A multicenter cluster randomized controlled trial with a 2×2 factorial design was performed to test the effectiveness of within‐visit and previsit DAs for localized prostate cancer, and minority men were oversampled. Methods: The interventions were delivered in urology practices affiliated with the NCI Community Oncology Research Program Alliance Research Base. The primary outcome was prostate cancer knowledge (percent correct on a 12‐item measure) assessed immediately after a urology consultation. Results: Four sites administered the previsit DA (39 patients), 4 sites administered the within‐visit DA (44 patients), 3 sites administered both previsit and within‐visit DAs (25 patients), and 4 sites provided usual care (50 patients). The median percent correct in prostate cancer knowledge, based on the postvisit knowledge assessment after the intervention delivery, was as follows: 75% for the pre+within‐visit DA study arm, 67% for the previsit DA only arm, 58% for the within‐visit DA only arm, and 58% for the usual‐care arm. Neither the previsit DA nor the within‐visit DA had a significant impact on patient knowledge of prostate cancer treatments at the prespecified 2.5% significance level (P =.132 and P =.977, respectively). Conclusions: DAs for localized prostate cancer treatment provided at 2 different points in the care continuum in a trial that oversampled minority men did not confer measurable gains in prostate cancer knowledge. This study oversamples minority men and evaluates the effect of 2 decision aids on prostate cancer patients' knowledge. Decision aids are not shown to affect knowledge about prostate cancer treatment options.
- Subjects
PROSTATE cancer; CLUSTER randomized controlled trials; PROSTATE cancer patients; CANCER treatment
- Publication
Cancer (0008543X), 2022, Vol 128, Issue 6, p1242
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34062